FibroGen, Inc., is a private biotechnology company developing novel drugs to arrest fibrosis and scarring in chronic conditions, such as lung fibrosis, scleroderma, liver fibrosis, and surgical adhesions, and in acute conditions, such as dermal scarring and reactive fibrosis following heart attack, as well as fibrotic complications of diabetes, for which there are no known therapies today. Additionally, leveraging its knowledge of extracellular matrix biology, FibroGen has developed the only known commercially viable methods for production of recombinant human collagens and gelatins, including the production of specifically designed synthetic gelatins based on particular portions of collagen molecules, for pharmaceutical, medical device, and many other markets, offering replacements for the animal carcass-derived materials currently available.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 03/28/05 | Series B | 107.2M | Palisade Capital Management, Southpaw Asset Management, Falvey Memorial Library, Villanova University., Churchill Navigation, Rally Capital Services LLC, Northwest Venture Associates, Madrona Venture Group LLC, mobile-worx, Softbank China Venture Capital, ACA Capital, New York City Investment Fun | Unknown |